Abstract
Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite of their high potency to suppress the alloimmune response (prevention of allograft rejection) which plays an essential role in the pathogenesis of CAV, the immunosuppressive regimens which were used in the past were not able to entirely prevent the development of CAV. This can be explained by the fact that several non-alloimmune insults such as brain death, organ preservation, surgical trauma, ischemia-reperfusion, diabetes, hypertension, hyperlipidemia, cytomegalovirus infection etc. are also involved in the development or progression of CAV. Some of these insults are not affected by immunosuppression, whereas others can be even aggravated by certain ISDs, particularly by calcineurin inhibitors (CNIs), but also by glucocorticosteroids and proliferation signal inhibitors (PSIs). Certain ISDs, especially CNIs, also have direct toxic effects on vascular endothelial and smooth muscle cells inducing endothelial dysfunction and proliferation of both smooth muscle cells and fibroblasts which promotes the development and progression of CAV. Other ISDs like PSIs and mycophenolate mofetil appeared able to delay the onset of CAV and reduce its progression, especially by their inhibitory effects on smooth muscle cell migration and proliferation. The present article reviews the data available on the impact of different ISDs and regimens on the development and progression of CAV.
Keywords: Heart transplantation, immunosuppression, allograft vasculopathy, coronary stenoses, outcome
Current Vascular Pharmacology
Title: Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Volume: 8 Issue: 5
Author(s): Michael Dandel and Roland Hetzer
Affiliation:
Keywords: Heart transplantation, immunosuppression, allograft vasculopathy, coronary stenoses, outcome
Abstract: Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite of their high potency to suppress the alloimmune response (prevention of allograft rejection) which plays an essential role in the pathogenesis of CAV, the immunosuppressive regimens which were used in the past were not able to entirely prevent the development of CAV. This can be explained by the fact that several non-alloimmune insults such as brain death, organ preservation, surgical trauma, ischemia-reperfusion, diabetes, hypertension, hyperlipidemia, cytomegalovirus infection etc. are also involved in the development or progression of CAV. Some of these insults are not affected by immunosuppression, whereas others can be even aggravated by certain ISDs, particularly by calcineurin inhibitors (CNIs), but also by glucocorticosteroids and proliferation signal inhibitors (PSIs). Certain ISDs, especially CNIs, also have direct toxic effects on vascular endothelial and smooth muscle cells inducing endothelial dysfunction and proliferation of both smooth muscle cells and fibroblasts which promotes the development and progression of CAV. Other ISDs like PSIs and mycophenolate mofetil appeared able to delay the onset of CAV and reduce its progression, especially by their inhibitory effects on smooth muscle cell migration and proliferation. The present article reviews the data available on the impact of different ISDs and regimens on the development and progression of CAV.
Export Options
About this article
Cite this article as:
Dandel Michael and Hetzer Roland, Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy, Current Vascular Pharmacology 2010; 8 (5) . https://dx.doi.org/10.2174/157016110792006923
DOI https://dx.doi.org/10.2174/157016110792006923 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters Editorial [ Obesity and the Lung Guest Editors: Neil S. Cherniack and E. Paul Cherniack ]
Current Respiratory Medicine Reviews Preface
Current Drug Targets - Cardiovascular & Hematological Disorders Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry Obesity- An Adverse Factor in Reproductive Age
Applied Clinical Research, Clinical Trials and Regulatory Affairs What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology Editorial [Hot Topic: Peripheral Proteins as Drug Targets (Guest Editor: Robert V. Stahelin) ]
Current Drug Targets Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry The Clinical Genetics of Psoriasis
Current Genomics Contribution of Large Animals to Translational Research on Prenatal Programming of Obesity and Associated Diseases
Current Pharmaceutical Biotechnology Pulmonary Hypertension and Lung Transplant in Connective Tissue Disease-Interstitial Lung Disease
Current Respiratory Medicine Reviews Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism Neuroprotective Effects of an Erythropoietin-Derived Peptide in PC1 2 Cells under Oxidative Stress
CNS & Neurological Disorders - Drug Targets MicroRNAs and Physical Activity
MicroRNA Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Recent Patents in Plant Biotechnology: Impact on Global Health
Recent Patents on Biotechnology